Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition (original) (raw)

• Deininger, M., Buchdunger, E. & Druker, B. J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640–2653 (2005).
  Article CAS PubMed Google Scholar
• Oeffinger, K. C. et al. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 355, 1572–1580 (2006). This work identifies the increased risk of cardiovascular toxicity in adults who have survived a childhood cancer, highlighting the importance of minimizing cardiovascular complications of cancer therapies.
  Article CAS PubMed Google Scholar
• Krause, D. S. & Van Etten, R. A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172–187 (2005).
  Article CAS PubMed Google Scholar
• Kerkela, R. et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Med. 12, 908–916 (2006). This work explores the mechanisms of cardiomyocyte toxicity associated with imatinib and identifies signalling pathways mediating the toxicity.
  Article PubMed CAS Google Scholar
• Motzer, R. J. et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
  Article CAS PubMed Google Scholar
• Chakko, S. et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am. J. Med. 90, 353–359 (1991).
  Article CAS PubMed Google Scholar
• Stevenson, L. W. & Perloff, J. K. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. J. Am. Med. Assoc. 261, 884–888 (1989).
  Article CAS Google Scholar
• Druker, B. J. et al. Efficacy and safety of a specific inhi-bitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).
  Article CAS PubMed Google Scholar
• Druker, B. J. et al. Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042 (2001).
  Article CAS PubMed Google Scholar
• Kantarjian, H. et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542–2551 (2006).
  Article PubMed Google Scholar
• Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).
  Article CAS PubMed Google Scholar
• Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).
  Article CAS PubMed Google Scholar
• Slaman, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
  Article Google Scholar
• Park, Y. H. et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett. 243, 16–22 (2006).
  Article CAS PubMed Google Scholar
• Fabian, M. A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnol. 23, 329–336 (2005). These researchers use a new technology to raise concerns about the non-selectivity of TKIs, particularly multi-targeted TKIs.
  Article CAS Google Scholar
• Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).
  Article CAS PubMed Google Scholar
• Seidman, A. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 20, 1215–1221 (2002).
  Article CAS PubMed Google Scholar
• Joensuu, H. et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809–820 (2006).
  Article CAS PubMed Google Scholar
• Gonzalez-Angulo, A. M., Hortobagyi, G. N. & Esteva, F. J. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11, 857–867 (2006).
  Article CAS PubMed Google Scholar
• Tan-Chiu, E. et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. 23, 7811–7819 (2005).
  Article CAS PubMed Google Scholar
• Bengala, C. et al. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br. J. Cancer 94, 1016–1020 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Ewer, M. S. et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 23, 7820–7826 (2005).
  Article CAS PubMed Google Scholar
• Perez, E. A. & Rodeheffer, R. Clinical cardiac tolerability of trastuzumab. J. Clin. Oncol. 22, 322–329 (2004).
  Article CAS PubMed Google Scholar
• Elliott, P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin. Oncol. 33, S2–S7 (2006).
  Article CAS PubMed Google Scholar
• Zhao, Y. Y. et al. Neuregulins promote survival and growth of cardiac myocytes. J. Biol. Chem. 273, 10261–10269 (1998).
  Article CAS PubMed Google Scholar
• Kuramochi, Y., Guo, X. & Sawyer, D. B. Neuregulin activates ERBB2-dependent Src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J. Mol. Cell. Cardiol. 41, 228–235 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, K. F. et al. Requirement for neuregulin receptor ERBB2 in neural and cardiac development. Nature 378, 394–398 (1995).
  Article CAS PubMed Google Scholar
• Gassmann, M. et al. Abberant neural and cardiac development in mice lacking the ERBB4 neuregulin receptor. Nature 378, 390–394 (1995).
  Article CAS PubMed Google Scholar
• Meyer, D. & Birchmeier, C. Multiple essential functions of neuregulin in development. Nature 378, 386–390 (1995).
  Article CAS PubMed Google Scholar
• Crone, S. A. et al. ERBB2 is essential in the prevention of dilated cardiomyopathy. Nature Med. 8, 459–465 (2002). References 30 and 31 describe the cardiac phenotype of knockout Erbb2 mice, thereby defining ERBB2 as an essential survival factor in the heart.
  Article CAS PubMed Google Scholar
• Ozcelik, C. et al. Conditional mutation of the ErbB2 (Her2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl Acad. Sci. USA 99, 8880–8885 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Burris, H. A. et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 23, 5305–5313 (2005).
  Article CAS PubMed Google Scholar
• Geyer, C. E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733–2743 (2006).
  Article CAS PubMed Google Scholar
• Sliwkowski, M. X. et al. Nonclincial studies addressing the mechanism of action of trastuzumab. Semin. Oncol. 26, 60–70 (1999).
  CAS PubMed Google Scholar
• Gordon, M. S. et al. Clinical activity of pertuzumab, a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol. 24, 4324–4332 (2006).
  Article CAS PubMed Google Scholar
• Menendez, J. A., Mehmi, I. & Lupu, R. Trastuzumab in combination with heregulin-activated Her-2 (_erb_B-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J. Clin. Oncol. 24, 3735–3746 (2006).
  Article CAS PubMed Google Scholar
• Grazette, L. et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J. Am. Coll. Cardiol. 44, 2231–2238 (2004). This work identifies a possible mechanism by which trastuzumab leads to cardiac dysfunction without apoptosis, and might provide a mechanism to understand the reversibility of this cardiotoxicity.
  Article CAS PubMed Google Scholar
• Potts, M. B., Vaughan, A. E., McDonough, H., Patterson, C. & Deshmukh, M. Reduced Apaf-1 levels in cardiomyocytes engage a strict regulation of apoptosis by endogenous XIAP. J. Cell Biol. 171, 925–930 (2005). This work identifies mechanisms by which cardiomyocytes may be uniquely resistant to apoptosis induced by the mitochondrial pathway.
  Article CAS PubMed PubMed Central Google Scholar
• Xia, W. et al. Combining lapatinib (GW572016), a small molecule inhibitor of ERBB1 and ERBB2 tyrosine kinses, with therapeutic anti-ERBB2 anti-bodies enhances apoptosis of ERBB2-overexpressing breast cancer cells. Oncogene 24, 6213–6221 (2005).
  Article CAS PubMed Google Scholar
• O'Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase myeloid leukemia. N. Engl. J. Med. 348, 994–1004 (2003).
  Article CAS PubMed Google Scholar
• Kantarjian, H., Jabbour, E., Grimley, J. & Kirkpatrick, P. Dasatinib. Nature Rev. Drug Discov. 5, 717–718 (2006).
  Article CAS Google Scholar
• Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531–2541 (2006).
  Article CAS PubMed Google Scholar
• Force, T. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nature Med. 13, 15–16 (2007).
  Article CAS Google Scholar
• Fromme, E. K., Eilers, K. M., Mori, M., Hsieh, Y. C. & Beer, T. M. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J. Clin. Oncol. 22, 3485–3490 (2004).
  Article PubMed Google Scholar
• Scharf, O. & Colevas, D. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J. Clin. Oncol. 24, 3933–3938 (2006).
  Article PubMed Google Scholar
• Dyck, J. R. B. & Lopaschuk, G. D. AMPK alterations in cardiac physiology and pathology: enemy or ally? J. Physiol. 574, 95–112 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Yuan, J., Lipinski, M. & Degterev, A. Diversity in the mechanisms of neuronal cell death. Neuron 15, 961–973 (2003).
  Google Scholar
• Ankarcrona, M. et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15, 961–973 (1995).
  Article CAS PubMed Google Scholar
• Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science 293, 876–880 (2001).
  Article CAS PubMed Google Scholar
• Li, B. et al. Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase Cδ. Genes Dev. 18, 1824–1837 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Cao, C., Leng, Y., Huang, W., Liu, X. & Kufe, D. Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases. J. Biol. Chem. 278, 39609–39614 (2003).
  Article CAS PubMed Google Scholar
• Cao, C., Leng, Y. & Kufe, D. Catalase activity is regulated by c-Abl and Arg in the oxidative stress response. J. Biol. Chem. 278, 29667–29675 (2003).
  Article CAS PubMed Google Scholar
• Cao, C. et al. Ubiquitination and degradation of the Arg tyrosine kinase is regulated by oxidative stress. Oncogene 24, 2433–2440 (2005).
  Article CAS PubMed Google Scholar
• Bristol-Myers Squibb. Sprycel (dasatinib) Prescribing Information [online] (2006).
• Zhang, K. & Kaufman, R. J. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 66, S102–S109 (2006).
  Article CAS PubMed Google Scholar
• Zhang, K. & Kaufman, R. J. Signaling the unfolded protein response from the endoplasmic reticulum. J. Biol. Chem. 279, 25935–25938 (2004).
  Article CAS PubMed Google Scholar
• Ron, D. Translational control in the endoplasmic reticulum stress response. J. Clin. Invest. 110, 1383–1388 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Steinberg, S. F. Distinctive activation mechanisms and functions for protein kinase C δ. Biochem. J. 384, 449–459 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Ito, Y. et al. Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic reticulum stress-induced apoptosis. Mol. Cell. Biol. 21, 6233–6242 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Sun, X., Wu, F., Datta, R., Kharbanda, S. & Kufe, D. Interaction between protein kinase C δ and the c-Abl tyrosine kinase in the cellular response to oxidative stress. J. Biol. Chem. 275, 7470–7473 (2000).
  Article CAS PubMed Google Scholar
• Pattacini, L. et al. Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 BCR–ABL tyrosine kinase. Leuk. Res. 28, 191–202 (2004).
  Article CAS PubMed Google Scholar
• Schermuly, R. T. et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 115, 2811–2821 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Abdollahi, A. et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J. Exp. Med. 201, 925–935 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, C.-H. et al. Stem cell factor deficiency is vasculoprotective. Circ. Res. 99, 617–625 (2006).
  Article CAS PubMed Google Scholar
• Branca, M. A. Multi-kinase inhibitors create buzz at ASCO. Nature Biotech. 23, 639 (2005).
  Article CAS Google Scholar
• Demetri, G. D. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329–1338 (2006).
  Article CAS PubMed Google Scholar
• Pfizer . Sutent (sunitinib) Prescribing Information [online](2007).
  Google Scholar
• Desai, J. et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann. Intern. Med. 145, 660–664 (2006).
  Article PubMed Google Scholar
• Hsieh, P. C., MacGillvray, C., Gannon, J., Cruz, F. U. & Lee, R. T. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 114, 637–644 (2006).
  Article CAS PubMed Google Scholar
• Terai, K. et al. AMP-activated protein kianse protects cardiomyocytes against hypoxic injury through attentuation of endoplasmic reticulum stress. Mol. Cell. Biol. 25, 9554–9575 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Bayer Pharmaceuticals. Nexavar (sorafenib) Prescribing Information [online](2006).
• Kyriakis, J. M., Force, T. L., Rapp, U. R., Bonventre, J. V. & Avruch, J. Mitogen regulation of c-Raf-1 protein kinase activity toward mitogen-activated protein kinase kinase. J. Biol. Chem. 268, 16009–16019 (1993).
  CAS PubMed Google Scholar
• Chen, J., Fujii, K., Zhang, L., Roberts, T. & Fu, H. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulated kinase 1 through a MEK–ERK-independent mechanism. Proc. Natl Acad. Sci. USA 98, 7783–7788 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• O'Neill, E., Rushworth, L., Baccarani, M. & Kolch, W. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306, 2267–2270 (2004).
  Article CAS PubMed Google Scholar
• Muslin, A. J. Role of Raf proteins in cardiac hypertrophy and cardiomyocyte survival. Trends Cardiovasc. Med. 15, 225–229 (2005).
  Article CAS PubMed Google Scholar
• Yamaguchi, O. et al. Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. Proc. Natl Acad. Sci. USA 100, 15883–15888 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• O'Neill, E. & Kolch, W. Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippl. Cell Cycle 4, 365–367 (2005).
  Article CAS PubMed Google Scholar
• Yamaguchi, O. et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J. Clin. Invest. 114, 937–943 (2004). References 78 and 79 describe essential functions of RAF1 in the heart, raising concerns about long-term use of RAF1 inhibitors.
  Article CAS PubMed PubMed Central Google Scholar
• Harris, I. S. et al. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 110, 718–723 (2004).
  Article CAS PubMed Google Scholar
• Shiojima, I. et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transtion to heart failure. J. Clin. Invest. 115, 2108–2118 (2005). References 80 and 81 highlight the critical role of angiogenesis in the adaptation to pressure loads on the heart.
  Article CAS PubMed PubMed Central Google Scholar
• Izumiya, Y. et al. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 47, 887–893 (2006).
  Article CAS PubMed Google Scholar
• Sano, M. et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446, 444–448 (2007).
  Article CAS PubMed Google Scholar
• Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661–665 (2007).
  Article CAS PubMed Google Scholar
• Negoro, S. et al. Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc. Res. 47, 797–805 (2000).
  Article CAS PubMed Google Scholar
• Hilfiker-Kleiner, D., Limbourg, A. & Drexler, H. STAT3-mediated activation of myocardial capillary growth. Trends Cardiovasc. Med. 15, 152–157 (2005).
  Article CAS PubMed Google Scholar
• Hilfiker-Kleiner, D. et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ. Res. 95, 187–195 (2004).
  Article CAS PubMed Google Scholar
• Kunisada, K. et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc. Natl Acad. Sci. USA 97, 315–319 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Smith, B. D. et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103, 3669–3676 (2004).
  Article CAS PubMed Google Scholar
• Ayach, B. B. et al. Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. Proc. Natl Acad. Sci. USA 103, 2304–2309 (2006). References 89 and 90 illustrate potential concerns about the effect of long-term inhibition of KIT on cardiac function after a heart attack.
  Article CAS PubMed PubMed Central Google Scholar
• Fazel, S. et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J. Clin. Invest. 116, 1865–1877 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• van Heeckeren, W. J. et al. Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J. Clin. Oncol. 24, 1485–1488 (2006).
  Article CAS PubMed Google Scholar
• Van Etten, R. A. & Shannon, K. M. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 6, 547–552 (2004).
  Article CAS PubMed Google Scholar
• Gilliland, D. G. & Tallman, M. S. Focus on acute leukemias. Cancer Cell 1, 417–420 (2002).
  Article CAS PubMed Google Scholar
• Cools, J. et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201–1214 (2003).
  Article CAS PubMed Google Scholar
• James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144–1148 (2005).
  Article CAS PubMed Google Scholar
• Golub, T. R., Barker, G. F., Lovett, M. & Gilliland, D. G. Fusion of PDGF receptor β to a novel _ets_-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77, 307–316 (1994).
  Article CAS PubMed Google Scholar
• Macdonald, D., Reiter, A. & Cross, N. C. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 107, 101–107 (2002).
  Article CAS PubMed Google Scholar
• Lacouture, M. E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Rev. Cancer 6, 803–812 (2006).
  Article CAS Google Scholar
• Cwynarski, K. et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18, 1332–1339 (2004).
  Article CAS PubMed Google Scholar
• Dietz, A. B. et al. Imatinib meylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104, 1094–1099 (2004).
  Article CAS PubMed Google Scholar
• Seggewiss, R. et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependen manner. Blood 105, 2473–2479 (2005).
  Article CAS PubMed Google Scholar
• Zipfel, P. A., Zhang, W., Quiroz, M. & Pendergast, A. M. Requirement for Abl kinases in T cell receptor signaling. Curr. Biol. 14, 1222–1231 (2004).
  Article CAS PubMed Google Scholar
• Gao, H. et al. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 19, 1905–1911 (2005).
  Article CAS PubMed Google Scholar
• Dewar, A. L., Doherty, K. V., Hughes, T. P. & Lyons, A. B. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol. Cell Biol. 83, 48–56 (2005).
  Article CAS PubMed Google Scholar
• Cebo, C. et al. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation. J. Immunol. 176, 864–872 (2006).
  Article CAS PubMed Google Scholar
• Wang, H. et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 105, 1135–1143 (2005).
  Article CAS PubMed Google Scholar
• Lavrik, I. N., Golks, A. & Krammer, P. H. Caspases: pharmacological manipulation of cell death. J. Clin. Invest. 115, 2665–2672 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Reed, J. C. Apoptosis-based therapies. Nature Rev. Drug Discov. 1, 111–121 (2002).
  Article CAS Google Scholar
• Foo, R. S., Mani, K. & Kitsis, R. N. Death begets failure in the heart. J. Clin. Invest. 115, 565–571 (2005).
  Article CAS PubMed PubMed Central Google Scholar